Optimizing health-related quality of life in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors

References

• Rosti G, Castagnetti F, Gugliotta G, et al. Tyrosine kinase inhibitors in chronic myeloid leukaemia: which, when, for whom? Nat Rev Clin Oncol. 2017 Mar;14(3):141–154.
   PubMed Web of Science ®Google Scholar
• Baccarani M, Deininger MW, Rosti G, et al. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood. 2013 Aug 8;122(6):872–884.
   PubMed Web of Science ®Google Scholar
• Hochhaus A, Saussele S, Rosti G, et al. Chronic myeloid leukaemia: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017 July 1;28(suppl_4):iv41–iv51.
   PubMed Web of Science ®Google Scholar
• Hochhaus A, Baccarani M, Silver RT, et al. European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. Leukemia. 2020 Apr;34(4):966–984.
   PubMed Web of Science ®Google Scholar
• Cortes JE, Saglio G, Kantarjian HM, et al. Final 5-year study results of DASISION: the dasatinib versus imatinib study in treatment-naive chronic myeloid leukemia patients trial. J Clin Oncol. 2016 July 10;34(20):2333–2340.
   PubMed Web of Science ®Google Scholar
• Hochhaus A, Saglio G, Hughes TP, et al. Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial. Leukemia. 2016 May;30(5):1044–1054.
   PubMed Web of Science ®Google Scholar
• Cortes JE, Gambacorti-Passerini C, Deininger MW, et al. Bosutinib versus imatinib for newly diagnosed chronic myeloid leukemia: results from the randomized BFORE trial. J Clin Oncol. 2018 Jan 20;36(3):231–237.
   PubMed Web of Science ®Google Scholar
• Steegmann JL, Baccarani M, Breccia M, et al. European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia. Leukemia. 2016 Aug;30(8):1648–1671.
   PubMed Web of Science ®Google Scholar
• Saglio G, Jabbour E. First-line therapy for chronic phase CML: selecting the optimal BCR-ABL1-targeted TKI. Leuk Lymphoma. 2018 July;59(7):1523–1538.
   PubMed Web of Science ®Google Scholar
• García-Gutiérrez V, Hernández-Boluda JC. Tyrosine kinase inhibitors available for chronic myeloid leukemia: efficacy and safety. Front Oncol. 2019;9:603.
   PubMed Web of Science ®Google Scholar
• Efficace F, Cannella L. The value of quality of life assessment in chronic myeloid leukemia patients receiving tyrosine kinase inhibitors. Hematology Am Soc Hematol Educ Program. 2016 Dec 2;2016(1):170–179.
   PubMedGoogle Scholar
• Kirkizlar O, Eskazan AE. Adverse events of tyrosine kinase inhibitors and their impact on quality of life in patients with chronic myeloid leukemia. Exp Rev Qual Life Cancer Care. 2016 Sept 2;1(5):353–359.
   Google Scholar
• Pinilla-Ibarz J, Cortes J, Mauro MJ. Intolerance to tyrosine kinase inhibitors in chronic myeloid leukemia: definitions and clinical implications. Cancer. 2011Feb15;117(4):688–697.
   PubMed Web of Science ®Google Scholar
• Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Plos Med. 2009;6(7):e1000097.
   Google Scholar
• Efficace F, Stagno F, Iurlo A, et al. Health-related quality of life of newly diagnosed chronic myeloid leukemia patients treated with first-line dasatinib versus imatinib therapy. Leukemia. 2020;34(2):488–498.
   PubMed Web of Science ®Google Scholar
• Cortes JE, Gambacorti-Passerini C, Deininger MW, et al. Patient-reported outcomes in the phase 3 BFORE trial of bosutinib versus imatinib for newly diagnosed chronic phase chronic myeloid leukemia. J Cancer Res Clin Oncol. 2019 June;145(6):1589–1599.
   PubMed Web of Science ®Google Scholar
• Zulbaran-Rojas A, Lin HK, Shi Q, et al. A prospective analysis of symptom burden for patients with chronic myeloid leukemia in chronic phase treated with frontline second- and third-generation tyrosine kinase inhibitors. Cancer Med. 2018 Nov;7(11):5457–5469.
   PubMed Web of Science ®Google Scholar
• Yu L, Wang H, Milijkovic D, et al. Achieving optimal response at 12 months is associated with a better health-related quality of life in patients with chronic myeloid leukemia: a prospective, longitudinal, single center study. BMC Cancer. 2018 Aug 3;18(1):782.
   PubMedGoogle Scholar
• Efficace F, Castagnetti F, Martino B, et al. Health-related quality of life in patients with chronic myeloid leukemia receiving first-line therapy with nilotinib. Cancer. 2018 May 15;124(10):2228–2237.
   PubMed Web of Science ®Google Scholar
• Hochhaus A, Masszi T, Giles FJ, et al. Treatment-free remission following frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: results from the ENESTfreedom study. Leukemia. 2017 July;31(7):1525–1531.
   PubMed Web of Science ®Google Scholar
• Hochhaus A, Gambacorti-Passerini C, Abboud C, et al. Bosutinib for pretreated patients with chronic phase chronic myeloid leukemia: primary results of the phase 4 BYOND study. Leukemia. 2020 Aug;34(8):2125–2137.
   PubMed Web of Science ®Google Scholar
• Clark RE, Polydoros F, Apperley JF, et al. De-escalation of tyrosine kinase inhibitor dose in patients with chronic myeloid leukaemia with stable major molecular response (DESTINY): an interim analysis of a non-randomised, phase 2 trial. Lancet Haematol. 2017 July;4(7):e310–e316.
   PubMed Web of Science ®Google Scholar
• Clark RE, Polydoros F, Apperley JF, et al. De-escalation of tyrosine kinase inhibitor therapy before complete treatment discontinuation in patients with chronic myeloid leukaemia (DESTINY): a non-randomised, phase 2 trial. Lancet Haematol. 2019 July;6(7):e375–e383.
   PubMed Web of Science ®Google Scholar
• Kim DW, Saussele S, Williams LA, et al. Outcomes of switching to dasatinib after imatinib-related low-grade adverse events in patients with chronic myeloid leukemia in chronic phase: the DASPERSE study. Ann Hematol. 2018 Aug;97(8):1357–1367.
   PubMed Web of Science ®Google Scholar
• Kantarjian HM, Mamolo CM, Gambacorti-Passerini C, et al. Long-term patient-reported outcomes from an open-label safety and efficacy study of bosutinib in Philadelphia chromosome-positive chronic myeloid leukemia patients resistant or intolerant to prior therapy. Cancer. 2018 Feb 1;124(3):587–595.
   PubMed Web of Science ®Google Scholar
• Sacha T, Gora-Tybor J, Wasak-Szulkowska E, et al. Quality of life and adherence to therapy in patients with chronic myeloid leukemia treated with nilotinib as a second-line therapy: a multicenter prospective observational study. Clin Lymphoma Myeloma Leuk. 2017 May;17(5):283–295.
   PubMed Web of Science ®Google Scholar
• Cella D, Jensen SE, Webster K, et al. Measuring health-related quality of life in leukemia: the functional assessment of cancer therapy – leukemia (FACT-Leu) questionnaire. Value Health. 2012 Dec;15(8):1051–1058.
   PubMed Web of Science ®Google Scholar
• EuroQol Group. EuroQol–a new facility for the measurement of health-related quality of life. Health Policy. 1990 Dec;16(3):199–208.
   PubMed Web of Science ®Google Scholar
• Wang J, Shen ZX, Saglio G, et al. Phase 3 study of nilotinib vs imatinib in Chinese patients with newly diagnosed chronic myeloid leukemia in chronic phase: ENESTchina. Blood. 2015 Apr 30;125(18):2771–2778.
   PubMed Web of Science ®Google Scholar
• Ware JE Jr., Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care. 1992 June;30(6):473–483.
   PubMed Web of Science ®Google Scholar
• Aaronson NK, Ahmedzai S, Bergman B, et al. The European organization for research and treatment of cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993 Mar 3;85(5):365–376.
   PubMed Web of Science ®Google Scholar
• Williams LA, Gonzalez AG, Ault P, et al. Measuring the symptom burden associated with the treatment of chronic myeloid leukemia. Blood. 2013 Aug 1;122(5):641–647.
   PubMed Web of Science ®Google Scholar
• Cortes JE, Lipton JH, Miller CB, et al. Evaluating the impact of a switch to nilotinib on imatinib-related chronic low-grade adverse events in patients with CML-CP: the ENRICH study. Clin Lymphoma Myeloma Leuk. 2016 May;16(5):286–296.
   PubMed Web of Science ®Google Scholar
• Basch E. Toward patient-centered drug development in oncology. N Engl J Med. 2013 Aug 1;369(5):397–400.
   PubMed Web of Science ®Google Scholar
• Saglio G, Kim DW, Issaragrisil S, et al. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med. 2010 June 17;362(24):2251–2259.
   PubMed Web of Science ®Google Scholar
• Kantarjian H, Shah NP, Hochhaus A, et al. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2010 June 17;362(24):2260–2270.
   PubMed Web of Science ®Google Scholar
• Kantarjian HM, Shah NP, Cortes JE, et al. Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION). Blood. 2012 Feb 2;119(5):1123–1129.
   PubMed Web of Science ®Google Scholar
• Sharf G, Marin C, Bradley JA, et al. Treatment-free remission in chronic myeloid leukemia: the patient perspective and areas of unmet needs. Leukemia. 2020 Aug;34(8):2102–2112.
   PubMed Web of Science ®Google Scholar
• Sogawa R, Kimura S, Yakabe R, et al. Anxiety and depression associated with tyrosine kinase inhibitor discontinuation in patients with chronic myeloid leukemia. Int J Clin Oncol. 2018 Oct;23(5):974–979.
   PubMed Web of Science ®Google Scholar
• Atallah E, Schiffer CA, Radich JP, et al. Assessment of outcomes after stopping tyrosine kinase inhibitors among patients with chronic myeloid leukemia: a nonrandomized clinical trial. JAMA Oncol. 2020 Nov 12. DOI:10.1001/jamaoncol.2019.5140
   PubMed Web of Science ®Google Scholar
• Cella D, Riley W, Stone A, et al. The patient-reported outcomes measurement information system (PROMIS) developed and tested its first wave of adult self-reported health outcome item banks: 2005–2008. J Clin Epidemiol. 2010 Nov;63(11):1179–1194.
   PubMed Web of Science ®Google Scholar
• Bower H, Bjorkholm M, Dickman PW, et al. Life expectancy of patients with chronic myeloid leukemia approaches the life expectancy of the general population. J Clin Oncol. 2016 Aug 20;34(24):2851–2857.
   PubMed Web of Science ®Google Scholar
• Atallah E, Schiffer CA. Discontinuation of tyrosine kinase inhibitors in chronic myeloid leukemia: when and for whom? Haematologica. 2020 Oct 9;Online ahead of print(12):2738–2745.
   Google Scholar
• Dueck AC, Mendoza TR, Mitchell SA, et al. Validity and reliability of the US national cancer institute’s patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE). JAMA Oncol. 2015 Nov;1(8):1051–1059.
   PubMed Web of Science ®Google Scholar
• Efficace F, Rosti G, Aaronson N, et al. Patient- versus physician-reporting of symptoms and health status in chronic myeloid leukemia. Haematologica. 2014 Apr;99(4):788–793.
   PubMed Web of Science ®Google Scholar
• Thanarajasingam G, Minasian LM, Baron F, et al. Beyond maximum grade: modernising the assessment and reporting of adverse events in haematological malignancies. Lancet Haematol. 2018 Nov;5(11):e563–e598.
   PubMed Web of Science ®Google Scholar
• Efficace F, Baccarani M, Breccia M, et al. International development of an EORTC questionnaire for assessing health-related quality of life in chronic myeloid leukemia patients: the EORTC QLQ-CML24. Qual Life Res. 2014 Apr;23(3):825–836.
   PubMed Web of Science ®Google Scholar
• Efficace F, Iurlo A, Patriarca A, et al. Validation and reference values of the EORTC QLQ-CML24 questionnaire to assess health-related quality of life in patients with chronic myeloid leukemia. Leuk Lymphoma. 2020 Nov;6:1–10.
   Google Scholar
• FACIT Searchable Library. [ cited 2020 Oct 2]. Available from: https://www.facit.org/facit-searchable-library
   Google Scholar
• EORTC Item Library. [ cited 2020 May 11]. Available from: https://www.eortc.be/itemlibrary/
   Google Scholar
• NCI-PRO-CTCAE Items-English. Item library version 1.0. [ cited 2020 Oct 2]. Available from: https://healthcaredelivery.cancer.gov/pro-ctcae/pro-ctcae_english.pdf
   Google Scholar
• Chakraborty R, Cannella L, Cottone F, et al. Quality of patient-reported outcome reporting in randomised controlled trials of haematological malignancies according to international quality standards: a systematic review. Lancet Haematol. 2020 Dec;7(12):e892–e901.
   PubMed Web of Science ®Google Scholar
• Calvert M, Kyte D, Mercieca-Bebber R, et al. Guidelines for inclusion of patient-reported outcomes in clinical trial protocols: the SPIRIT-PRO extension. JAMA. 2018 Feb 6;319(5):483–494.
   PubMed Web of Science ®Google Scholar
• Coens C, Pe M, Dueck AC, et al. International standards for the analysis of quality-of-life and patient-reported outcome endpoints in cancer randomised controlled trials: recommendations of the SISAQOL consortium. Lancet Oncol. 2020 Feb;21(2):e83–e96.
   PubMed Web of Science ®Google Scholar